Copy
View this email in your browser
Share Share
Tweet Tweet
Forward Forward

Update for Primary Care

Our latest primary care news and guidance.
 
February 2022
COVID-19News | Clinical knowledge summaries | Into practice | Get involved | Announcements

COVID-19

Updates to managing COVID-19 guideline

We have added a new recommendation to our rapid guideline on managing COVID-19 on neutralising monoclonal antibodies for people with COVID-19 who are not in hospital.

We are continuously updating our COVID-19 guidelines to incorporate the latest evidence and keep abreast of new developments in diagnosing and treating COVID-19. We’ll highlight recent updates in this monthly email communication, or you can keep up to date on the latest live changes through our website.

News

A picture of the actual drug Wegovy

New drug for people living with obesity

Thousands of people living with obesity are set to benefit from a new drug that could help reduce their weight by more than 10 per cent. Our new draft guidance recommends semaglutide is offered as an option for weight management, alongside a reduced-calorie diet and increased physical activity. Adults must have at least 1 weight-related condition and a body mass index (BMI) of at least 35 kg/m2, or exceptionally, a BMI of 30.0 kg/m2 to 34.9 kg/m2 to be considered for treatment. Evidence submitted shows that people lose more weight with semaglutide alongside supervised weight loss coaching than with support alone. Consultation is open until Tuesday 1 March 2022.

DNA strand in test tubes

First gene therapy for rare genetic neurodegenerative disorder in children

We've published draft guidance recommending gene therapy atidarsagene autotemcel as a one-off treatment for some children with the rare, life-limiting neurodegenerative condition metachromatic leukodystrophy (MLD). Clinical evidence suggests that atidarsagene autotemcel improves motor and cognitive function in the short term and could correct the enzyme deficiency caused by the disease. It is thought there are around 5 children born each year in England with MLD. Costing around £2.8 million at its list price, this one-off treatment is the most expensive drug NICE has ever evaluated. 

Catch up on all our latest news articles
NICE Talks logo

The Evidence Standards Framework for digital health technologies

In this episode of our NICE Talks podcast, Mark Salmon, programme director at NICE and Andrew Davies, digital health lead at the Association of British HealthTech Industries discuss our Evidence Standards Framework for digital health technologies. The framework helps developers and adopters of digital health technologies ensure new technologies are clinically effective and offer economic value.

Clinical knowledge summaries

New topics and updates on the site since the start of February include:

  • Postnatal care is a new topic based on our guidance on postnatal care. It covers the routine postnatal care that women should receive in the first 8 weeks after giving birth.
  • Safeguarding adults in care homes is a new topic. The recommendations are based on our guideline on safeguarding adults in care homes and underpinned by the Care Act 2014, the Care Act 2014 statutory guidance, and the Making Safeguarding Personal Framework.
  • Nausea/vomiting in pregnancy was updated in line with our guideline on antenatal care and Royal College of Obstetricians and Gynaecologists 2016 guidance. Under 'management scenario', the drug treatments section has been amended to include chlorpromazine as an option, and doxylamine with pyridoxine as an option.
  • Glaucoma was updated to include first-line therapeutic changes in secondary care management. If people have an intraocular pressure of 24mmHg or more and are at risk of visual impairment first-line treatment is 360° selective laser trabeculoplasty. This recommendation is based on our updated guideline glaucoma: diagnosis and management.
  • DMARDs was amended. The indications for the disease-modifying anti-rheumatic drugs (DMARDs) have been removed and links were included to the British National Formulary and the electronic Medicines Compendium. The scenario 'Gold - intramuscular' was removed.
Our CKS provide primary care practitioners with a readily accessible summary of the evidence base and best practice guidance for over 370 topics. These cover over 1,000 clinical presentations or patient scenarios, free to access in the UK.

Into practice

BNF app screen capture

BNF app introducing new login and favourites functionality

The BNF app is introducing new favourites functionality. It will allow registered users to login and bookmark drug monographs, treatment summaries and other records referred to frequently. This will allow users to easily find and quickly access this content across multiple devices.

Registration is required to help support the new feature. It’s quick and easy to do and once logged in, you will stay signed in on your device. Registration will be optional for 30 days from Monday 28 February 2022. During this time, users will be able to skip the registration process and access the app as usual. After 30 days, all users will be required to register.

Improving outcomes for cardiovascular disease (CVD)

The Accelerated Access Collaborative’s (AAC) lipid management rapid uptake product working group aims to remove barriers to the uptake of 3 NICE recommended lipid-lowering therapies:

  • high intensity statins
  • ezetimibe
  • PCSK9 inhibitors.
To support best treatment for patients with hypercholesterolaemia, the working group has developed 2 NICE-endorsed clinical pathways. These incorporate a number of our guidelines and technology appraisals:

The AAC has also produced a slide deck updating on their progress. This includes a list of resources (Slide 4) to help improve patient lipid management outcomes.

Get involved

Comment on a consultation

Our current consultations include:

Consultation is a key part of our guidance development process. It enables those with an interest in our guidance to comment at specific stages and feedback into the decision-making process.
See all our open consultations

Join a committee

We’re looking for healthcare professionals including a dentist, 3 GPs, a nurse and a prescribing clinical pharmacist working in primary care.

Our guidance and quality standards are developed by independent committees. Join us and have an active role in producing a guideline or quality standard.
See all our committee vacancies

Observe a meeting

We’re currently holding all our public meetings virtually. You'll need to register in advance to join. 

Upcoming public meeting:

  • Tuesday 8 March 2022 – Indicator advisory committee
    Registration closes Tuesday 1 March 2022.
    Agenda and register
Our advisory committee meetings, technology appraisal appeal hearings and public board meetings are open to the public. Holding them in public supports our commitment to having processes in place that are rigorous, open, and transparent.
See all our public meetings

Announcements

Consultation on Evidence-based Interventions Programme

The Academy of Medical Royal Colleges (AMRC) is consulting on the latest set of guidance (List 3) for their Evidence-based Interventions Programme.
 
The programme provides guidance on when it is and is not appropriate to carry out specific interventions. It aims to improve quality of care and optimise the use of NHS resources. The new guidance covers 17 interventions across a range of specialisms.

The consultation is open until Thursday 31 March 2022.

Share your views on the AMRC Evidence-based Interventions list

Price increase for technology appraisals and highly specialised technologies

We are increasing our charges for technology and highly specialised technology appraisals. The updated fees will apply to evaluations with a formal start date (invitation to participate) on or after 1 April 2022. Small companies meeting the criteria will continue to receive a 75% discount.

View updated charges
Instagram
Instagram
Facebook
Facebook
Twitter
Twitter
SoundCloud
SoundCloud
YouTube
YouTube
LinkedIn
LinkedIn

unsubscribe from this list